Healthcare > Pharmaceuticals & Biotechnology
•2434 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2434)
| Company | Market Cap | Price |
|---|---|---|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$1.11M |
$4.27
+7.29%
|
|
PRPH
ProPhase Labs, Inc.
BE-Smart uses a biomarker-based diagnostic panel, aligning with companion diagnostics.
|
$1.02M |
$0.36
+47.96%
|
|
INIS
International Isotopes Inc.
Core product: INIS manufactures radiopharmaceutical drugs (I-131) used for diagnostic imaging and therapy.
|
$580409 |
$0.06
|
|
CDT
CDT Equity Inc.
AZD1656/AZD5658 are small-molecule therapeutics licensed for development.
|
$577957 |
$1.47
-2.98%
|
|
SLRX
Salarius Pharmaceuticals, Inc.
Salarius operates as a clinical-stage biotech focused on oncology therapies (e.g., LSD1 inhibitor seclidemstat) and develops cancer treatments.
|
$397571 |
$0.74
-5.36%
|
|
ZVSA
ZyVersa Therapeutics, Inc.
IC 100 is a humanized monoclonal IgG4 antibody targeting ASC, classifiable as Monoclonal Antibody Therapeutics.
|
$359547 |
$0.14
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$267604 |
$2.57
-4.46%
|
|
NLSP
NLS Pharmaceutics AG
Kadimastem's allogeneic cell-therapy platform (IsletRx, AstroRx) and NLSP's merger create a clear Cell Therapy business line.
|
$229673 |
$0.79
-58.24%
|
|
RGBP
Regen BioPharma, Inc.
RGBP focuses on oncology/s Cancer immunotherapy and regenerative medicine, aligning with Biotech - Oncology.
|
$224038 |
$0.01
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$35790 |
$12.71
-4.29%
|
|
CERO
CERo Therapeutics Holdings, Inc.
CERO Therapeutics develops oncology-focused immunotherapies, including CER-T engineered T-cell therapies for cancer.
|
$23166 |
$0.10
+44.29%
|
|
EMMA
Emmaus Life Sciences, Inc.
Endari is an oral small-molecule therapeutic (L-glutamine) marketed by Emmaus Life Sciences for sickle cell disease.
|
$14040 |
$0.01
|
|
SMFL
Smart for Life, Inc.
SMFL owns manufacturing facilities (BSNM and DSO) and provides contract manufacturing for branded and contract-made nutraceutical products.
|
$558 |
$0.00
|
|
NCNA
NuCana plc
NuCana is a clinical-stage oncology biotech focusing on cancer therapeutics (NUC-3373 and NUC-7738).
|
N/A |
$3.68
-0.54%
|
Showing page 25 of 25 (2434 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
